<DOC>
	<DOCNO>NCT01761591</DOCNO>
	<brief_summary>The purpose randomize control trial ( RCT ) demonstrate clinical benefit impact resource utilization percutaneous coronary intervention ( PCI ) Svelte Acrobat Stent System compare CE mark bare metal stent ( BMS ) implantable via direct stenting lesion pre-dilation , patient coronary lesion eligible direct stenting recruit treated reflect real-life routine practice .</brief_summary>
	<brief_title>Acrobat Coronary Stent System Effectiveness European Study</brief_title>
	<detailed_description>The main objective study test follow hypothesis : 1 . The evaluated stent clinically non-inferior control BMS term freedom MACE 2 . The evaluated stent clinically beneficial compare control BMS reduce exposure radiation , amount contrast medium administer , procedure time , well amount administer heparin , 3 . The evaluated stent result frequent adverse event control BMS , 4 . The evaluated stent improves direct stenting success decrease procedural success compare control BMS . 5 . Resource utilization ( R.U . ) : 1 . Hospital-perspective resource utilization index admission index procedure great evaluate stent potentially low control BMS 2 . Resource utilization 6-month time-horizon , relation routine follow-up MACE , great evaluate stent control BMS .</detailed_description>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<criteria>Eligible PCI demonstrate native vessel vein/arterial graft disease symptomatic CAD : either stable angina pectoris ( CCS 1 , 2 , 3 pr 4 ) unstable ( Braunwald Class 13 , BC ) positive functional ischemia study Male postmenopausal female Patient provide write informed consent prior procedure Patient willing comply protocol Acceptable candidate CABG Patient indicate stenting one de novo stenotic lesion native coronary artery bypass graft without direct stenting All target lesion stenting single multivessel disease meet inclusion criterion None lesion require stenting Drug elute stent At least one lesion visually estimate candidate direct stenting All target lesion stenting visually estimatd RVD &gt; = 2.5 mm &lt; = 3.5 mm All target lesion stenting visually estimate LL = &lt; 20 mm ( cover lesion 1 stent ) All target lesion stenting visually estimate stenosis &gt; 50 % &lt; 99 % All target lesion stenting ACS lesion TIMI flow &gt; = 1 Currently enrol another clinical trial complete primary endpoint clinically interfere current study endpoints A previous coronary procedure within 30 day Any target lesion ( ) require treatment device PTCA prior stent placement ( , limit , directional coronary atherectomy , excimer laser , rotational atherectomy , etc . ) Previous BMS deployment anywhere target vessel within past 6 month Any DES deployment anywhere target vessel within past 9 month Any previous stent placement within 10 mm ( proximal distal ) target lesion Patient diabetes mellitus Comorbid condition ( ) could limit patient 's participation impact trial Documented LVEF &lt; 30 % recent evaluation Evidence AMI within 72 hour intend trial procedure and/or TIMI flow 0 History CVA TIA last 6 month Leukopenia ( &lt; 3.5 x 10^9/L ) Neutropenia ( &lt; 1000/mm3 ) &lt; = 3 day prior enrollment Thrombocytopenia ( &lt; 10^5/mm3 ) preprocedure Active peptic ulcer active GI bleed History bleed diathesis coagulopathy inability accept blood transfusion Known hypersensitivity contraindication aspirin , heparin bivalirudin , clopidogrel ticlopidine , cobalt , nickel , L605 Cobalt chromium alloy sensitivity contrast medium , adequately premedicated Serum creatinine level &gt; 2.5 mg per dl within 7 day prior index procedure Instent restenosis Patient able give consent read write protect law guardianship deprive civil right Woman childbearing age Patient cover health social insurance Unprotected leave main CAD obstruction &gt; 50 % , protect least one nonobstructed bypass graft LAD leave circumflex ( LCX ) artery branch Target vessel exhibit multiple lesion &gt; 40 % diameter stenosis outside range 5 mm proximal distal target lesion ( ) stented base visual estimate online QCA Any target lesion stenting exhibit intraluminal thrombus ( occupy &gt; 50 % true lumen diameter ) time Any target lesion stenting excessively tortuous ( two bend &gt; 90Â° reach target lesion ) Lesion location aortoostial within 5 mm origin LAD LCX Any target lesion stenting side branch &gt; 2.0 mm diameter bifurcation stenting plan Any target lesion &gt; 20 mm Any target lesion totally occlude ( CTO ) Any target lesion TIMI flow = 0 Any target lesion ISR</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2014</verification_date>
	<keyword>CAD</keyword>
	<keyword>PCI</keyword>
	<keyword>BMS</keyword>
	<keyword>Svelte</keyword>
	<keyword>Acrobat</keyword>
	<keyword>direct stenting</keyword>
	<keyword>RCT</keyword>
</DOC>